Pharm/Biotech
Resources

Outsourcing Guide

Cont. Education

Software/Reports

Training Courses

Web Seminars

Jobs

Buyer's Guide

Home Page

Pharm Patents /
Licensing

Pharm News

Federal Register

Pharm Stocks

FDA Links

FDA Warning Letters

FDA Doc/cGMP

Pharm/Biotech Events

Consultants

Advertiser Info

Newsletter Subscription

Web Links

Suggestions

Site Map
 

 

 

 

Title:  Ketosis-treating agent

United States Patent:  6,620,967

Issued:  September 16, 2003

Inventors:  Kobayashi; Hisamine (Kanagawa, JP)

Assignee:  Ajinomoto Co., Inc. (Tokyo, JP)

Appl. No.:  690016

Filed:  October 17, 2000

Abstract

A ketosis-treating agent comprising, as an active ingredient, at least one amino acid selected from valine, isoleucine, serine, glutamine and glutamic acid, or a peptide or protein comprising at least one amino acid selected from valine, isoleucine, serine, glutamine and glutamic acid; a method for treating or preventing ketosis, comprising administering to a human or animal an effective amount of the above agent; and a method for treating or preventing symptoms relating to ketone bodies, comprising administering to a human or animal an effective amount of the above agent.

SUMMARY OF THE INVENTION

An object of the present invention is to provide a ketosis-treating agent which does not increase a blood glucose value and shows extremely little influence on glucose metabolism, in view of the circumstances that there are many cases where glucose metabolism is disordered in a ketosis state as described above.

A further object of the present invention is to provide a ketosis-treating agent which does not require frequent administration and has long duration of the effect.

The present invention relates to a ketosis-treating agent comprising, as an active ingredient, at least one amino acid selected from valine, isoleucine, serine, glutamine and glutamic acid, or a peptide or protein comprising at least one amino acid selected from valine, isoleucine, serine, glutamine and glutamic acid.

Furthermore, the present invention relates to a method for treating or preventing ketosis, comprising administering to a human or animal an effective amount of the above agent.

Moreover, the present invention relates to a method for treating or preventing symptoms relating to ketone bodies, comprising administering to a human or animal an effective amount of the above agent.

DETAILED DESCRIPTION OF THE INVENTION

As a result of intensive studies for solving the above-described problems, the present inventors have found that valine, isoleucine, or serine is effective as a ketosistreating agent which does not increase a blood glucose value and shows extremely little influence on glucose metabolism as the first embodiment.

Also, they have found that valine, isoleucine, glutamine, or glutamic acid is effective as a ketosistreating agent which has long duration of the effect as the second embodiment.

The amino acids used in the first embodiment include valine, isoleucine, and serine, and, in view of long duration of the effect, valine and isoleucine are particularly preferred.

The amino acids used in the second embodiment include valine, isoleucine, glutamine and glutamic acid, and, in view of no increase of a blood glucose value and extremely little influence on glucose metabolism, valine and isoleucine are particularly preferred.

Furthermore, in the present invention, a peptide or protein comprising at least one amino acid among these as a component can be used, and a composition comprising at least one selected from these amino acids, peptides and proteins can also be used.

In the present invention, among the amino acids, peptides and proteins, the amino acids and peptides are more preferred, from the viewpoint of an immediate effect and capability in administering a large amount of the objective substance. Among these, the amino acids are most preferred.

The peptides and proteins used in the present invention, including amino acid numbers, molecular weights, properties and the like, are not particularly limited so long as they include at least one amino acid selected from valine, isoleucine, serine, glutamine and glutamic acid, but they are preferably peptides or proteins which can release the amino acids used in the present invention in a living body after the administration. Also, other amino acids constituting the peptides and proteins are not particularly limited.

The amino acids used in the present invention include usual amino acids, such as those used for pharmaceuticals, livestock feed, food, and the like.

A method for administering the ketosis-treating agent of the present invention is not particularly limited, and it may be administered according to a medical or veterinary medical method as a medicament, a food, or a feed, or as a mixture thereof, optionally together with a carrier, diluent, additive or the like.

Examples of the medicament of the present invention include tablets, powders, granules, fine particles, solutions, and the like. Such a preparation can be produced by making the ketosis-treating agent of the present invention and a pharmaceutically acceptable carrier, diluent, additive or the like into desired forms in the conventional way.

The ketosis-treating agent of the present invention can be applied to foods or feeds effectively. Examples of the foods or feeds containing the ketosis-treating agent include those which can be ingested immediately as such, are ingested after carrying out cooking and the like, and are premixed materials for use in food or feed production.

The dose and frequency of the administration vary depending on the symptoms of ketosis, but generally, it is preferred to administer the ketosis-treating agent at an amount of 20 to 500 mg as amino acids per kg of body weight, once per one to three days.

The ketosis-treating agent of the present invention is administered to a living body in order to reduce the concentration of ketone bodies in a body fluid, such as blood, urine, milk, or the like, or in a living body, or to prevent the increase of the concentration of ketone bodies, and includes those administered for the purpose of improving, treating or preventing various symptoms relating to ketone bodies in a living body.

Examples of the various symptoms relating to ketone bodies include starvation, diabetes, hepatophosphorylase deficiency, acetonemic vomiting, fructose-bisphosphatase deficiency, congenital disorder of organic acid metabolism (e.g., methylmalonic acidemia, propionic acidemia, isovaleric acidemia, hyperlactacidemia, etc.), 3-ketoacid-CoA transferase deficiency, and the like.

The present invention provides a ketosis-treating agent which is easy to control due to little influence on glucose metabolism and is administered less frequently due to long duration of the effect.

Claim 1 of 4 Claims

What is claimed is:

1. A method for treating ketosis, comprising administering to a human or animal an effective amount of a composition comprising at least one amino acid selected from the group consisting of valine, isoleucine, and serine, wherein said amino acid is administered in an amount of 20 to 500 mg per kg body weight effective to reduce ketone bodies, and wherein said composition is administered intravenously, and wherein said ketosis is caused by diabetes.




____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.

 

 

[ Outsourcing Guide ] [ Cont. Education ] [ Software/Reports ] [ Training Courses ]
[ Web Seminars ] [ Jobs ] [ Consultants ] [ Buyer's Guide ] [ Advertiser Info ]

[ Home ] [ Pharm Patents / Licensing ] [ Pharm News ] [ Federal Register ]
[ Pharm Stocks ] [ FDA Links ] [ FDA Warning Letters ] [ FDA Doc/cGMP ]
[ Pharm/Biotech Events ] [ Newsletter Subscription ] [ Web Links ] [ Suggestions ]
[ Site Map ]